` CRMD (CorMedix Inc) vs S&P 500 Comparison - Alpha Spread

CRMD
vs
S&P 500

Over the past 12 months, CRMD has significantly outperformed S&P 500, delivering a return of +43% compared to the S&P 500's +14% growth.

Stocks Performance
CRMD vs S&P 500

Loading
CRMD
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CRMD vs S&P 500

Loading
CRMD
S&P 500
Difference
www.alphaspread.com

Performance By Year
CRMD vs S&P 500

Loading
CRMD
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
CorMedix Inc vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

CorMedix Inc
Glance View

CorMedix, Inc. operates as a pharmaceutical and medical device company. The company is headquartered in Berkeley Heights, New Jersey and currently employs 29 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm's primary focus is on the development of its product candidate, DefenCath. The firm has in-licensed the rights to develop and commercialize its product candidate DefenCath. The DefenCath is a novel anti-infective solution intended for the reduction of catheter-related infections in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. DefenCath product is available in Europe and other territories under the brand name Neutrolin.

CRMD Intrinsic Value
20.68 USD
Undervaluation 42%
Intrinsic Value
Price
Back to Top